Acute megakaryoblastic leukemia laboratory findings: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 4: | Line 4: | ||
The diagnosis of AMKL (M7) is based on the following: | The diagnosis of AMKL (M7) is based on the following: | ||
# Bone marrow biopsy | #Bone marrow biopsy demonstrating 30% or more leukemic cells | ||
# Conducting tests that detect platelet-specific antibodies. | #Conducting tests that detect platelet-specific antibodies which could be monoclonal or polyclonal. | ||
==References== | ==References== | ||
Revision as of 19:11, 3 April 2021
|
Acute megakaryoblastic leukemia Microchapters |
|
Differentiating Acute megakaryoblastic leukemia from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Acute megakaryoblastic leukemia laboratory findings On the Web |
|
American Roentgen Ray Society Images of Acute megakaryoblastic leukemia laboratory findings |
|
Acute megakaryoblastic leukemia laboratory findings in the news |
|
Blogs on Acute megakaryoblastic leukemia laboratory findings |
|
Directions to Hospitals Treating Acute megakaryoblastic leukemia |
|
Risk calculators and risk factors for Acute megakaryoblastic leukemia laboratory findings |
The diagnosis of AMKL (M7) is based on the following:
- Bone marrow biopsy demonstrating 30% or more leukemic cells
- Conducting tests that detect platelet-specific antibodies which could be monoclonal or polyclonal.